Physician profile
Robert Greenig
NPI 1215567714
$3,321.78
in general payments reported to CMS, 2019-2025
14 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $152 · 2023: $1,042 · 2024: $1,081 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,105 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.78 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $906.92 | 2022-2025 | Caplyta |
| Abbvie INC. | $845.89 | 2022-2025 | |
| Axsome Therapeutics, INC. | $386.26 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $268.34 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $222.67 | 2024-2025 | Fanapt |
| Alkermes, INC. | $213.83 | 2023-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $149.99 | 2023 | Invega Trinza, Invega Sustenna |
| Lundbeck LLC | $103.91 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $100.52 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $35.23 | 2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $30.70 | 2024-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $22.89 | 2025 | |
| Idorsia Pharmaceuticals US INC | $21.05 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $13.58 | 2025 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Greenig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.